Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors54
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)53
Whole genome characterization of patient-derived lung cancer organoids43
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study40
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report39
Targeting ferroptosis to overcome drug resistance in lung cancer35
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203033
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China30
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes29
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series28
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report28
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling28
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer28
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer27
Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China26
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network26
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk26
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer26
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression25
Real-world data on severe lung cancer: a multicenter retrospective study25
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer25
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer24
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety24
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA23
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study23
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic23
0.22146821022034